NCT07000851 Imaging Studies in Corticobasal Syndrome
| NCT ID | NCT07000851 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jennifer Whitwell |
| Condition | Cortico Basal Degeneration |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-06-25 |
| Primary Completion | 2030-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2025-06-25 with a primary completion date of 2030-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Meet possible or probable CBS criteria Exclusion Criteria: * Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc) * Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome * Subjects will be excluded if they have a mutation in the progranulin gene * Subjects will excluded if they have received anti-Aβ therapy * Women who are pregnant will be excluded * Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc) * Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning
Contact & Investigator
Jennifer Whitwell, Ph.D.
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT07000851 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cortico Basal Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07000851 currently recruiting?
Yes, NCT07000851 is actively recruiting participants. Contact the research team at meyer.megan6@mayo.edu for enrollment information.
Where is the NCT07000851 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT07000851 clinical trial?
NCT07000851 is sponsored by Jennifer Whitwell. The principal investigator is Jennifer Whitwell, Ph.D. at Mayo Clinic. The trial plans to enroll 80 participants.